Table 1.

Clinical phenotype of study participants at enrolment

VariableRTRSCC (n=59)RTRNo (n=58)P Value
Caucasiana58 (98)55 (95)0.36
Male41 (71)39 (67)0.21
Age (years)66 (58–74)61 (55–67)0.03
Body mass index (kg/m2)25.2 (21.7–28.2)26.2 (23.2–29.7)0.09
Age at first transplant (years)43 (31–52)40 (32–49)0.30
Dialysis before transplant44/56 (79)44/56 (79)1.00
Duration of dialysis (months)14 (7–36)13 (7–25)0.53
Total duration of immunosuppression (months)b283 (208–353)249 (203–312)0.17
Received more than one transplant13 (22)10 (17)0.56
Induction therapy0.53
None51 (86)48 (83)
Anti-CD255 (9)6 (10)
Thymoglobulin3 (5)4 (7)
Previously treated for rejection32/54 (59)22/54 (41)0.05
Number of times treated2 (1–3)2 (1–3)0.42
Number of HLA-ABDR mismatches2 (2–4)2 (1–4)0.71
Serum creatinine (mmol/l)117 (90–168)126 (106–161)0.27
eGFR (ml/min per 1.73 m2)50.9 (35.5–64.0)44.2 (34.0–57.5)0.19
Cytomegalovirus IgG seropositive40 (68)36 (62)0.52
Immunosuppression:
Calcineurin inhibitor49 (83)47 (81)0.78
Azathioprine46 (78)38 (66)0.14
Mycophenolate4 (7)9 (16)0.15
Prednisolone24 (41)22 (38)0.76
Sirolimus4 (7)2 (3)0.35
Daily dosage (mg/kg)c
Ciclosporin1.90 (1.60–2.90)2.05 (1.58–2.55)0.81
Tacrolimus0.06 (0.06–0.10)0.06 (0.04–0.08)0.25
Azathioprine0.85 (0.55–1.13)0.80 (0.58–1.20)0.85
Mycophenolate11.9 (7.9–15.1)14.6 (13.0–19.0)0.28
Prednisolone0.07 (0.06–0.08)0.06 (0.05–0.07)0.12
Trough level (ng/ml)d
Ciclosporin76 (54–104)83 (59–100)0.80
Tacrolimus7.4 (6.3–9.4)6.5 (5.7–7.8)0.32
Smoker (>1 pack-year history)20 (34)23 (40)0.52
Previous non-NMSC malignancy5 (9)11 (19)0.10
History of malignancy in parents/siblings31 (53)20 (35)&0.04
Chronic UV exposure [5]38 (64)32 (55)0.31
Fitzpatrick skin type0.07
Type I–II27 (47)17 (29)
Type III–VI29 (51)41 (71)
Type V–VI1 (2)0
Nonbrown eye color44 (75)37 (65)0.26
Harden risk score [12]5.26 (4.2–6.16)4.96 (4.35–5.82)0.43
Urwin risk score [6]2 (1–3)1.5 (0–2)0.01
Harwood risk score [5]4 (2–4)3 (2–4)0.10
  • Continuous variables are reported as median (IQR) while categorical variables are reported as number (percentage of column). Where there are missing data, a denominator of number of known values in that column is given.

  • a Two participants were adopted and thus were unable to provide a family history.

  • b Including pretransplant immunosuppression where appropriate.

  • c Daily dosage is reported as a median (IQR) across RTRs receiving that medication.

  • d If below limit of detection, was given value 1 unit below this (i.e. if <30 ng/ml, given value 29 ng/ml).